Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. Facchini G, et al. Among authors: nasti g. Cancer Biol Ther. 2010 Sep 15;10(6):543-8. doi: 10.4161/cbt.10.6.12611. Epub 2010 Sep 8. Cancer Biol Ther. 2010. PMID: 20657175 Clinical Trial.
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
Vaccher E, Spina M, di Gennaro G, Talamini R, Nasti G, Schioppa O, Vultaggio G, Tirelli U. Vaccher E, et al. Among authors: nasti g. Cancer. 2001 Jan 1;91(1):155-63. doi: 10.1002/1097-0142(20010101)91:1<155::aid-cncr20>3.0.co;2-b. Cancer. 2001. PMID: 11148572 Clinical Trial.
Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients.
Spina M, Vaccher E, Juzbasic S, Milan I, Nasti G, Talamini R, Fasan M, Antinori A, Nigra E, Tirelli U. Spina M, et al. Among authors: nasti g. Cancer. 2001 Jul 1;92(1):200-6. doi: 10.1002/1097-0142(20010701)92:1<200::aid-cncr1310>3.0.co;2-a. Cancer. 2001. PMID: 11443628 Clinical Trial.
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Iaffaioli RV, Formato R, Tortoriello A, Del Prete S, Caraglia M, Pappagallo G, Pisano A, Gebbia V, Fanelli F, Ianniello G, Cigolari S, Pizza C, Marano O, Pezzella G, Pedicini T, Febbraro A, Incoronato P, Manzione L, Ferrari E, Marzano N, Quattrin S, Pisconti S, Nasti G, Giotta G, Colucci G; Southern Italy Oncology Group. Iaffaioli RV, et al. Among authors: nasti g. Br J Cancer. 2005 May 9;92(9):1621-5. doi: 10.1038/sj.bjc.6602579. Br J Cancer. 2005. PMID: 15856035 Free PMC article. Clinical Trial.
A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications.
Facchini G, Fiore F, Caraglia M, D'Angelo R, Nasti G, Caponigro F, Formato R, Budillon A, Iaffaioli RV. Facchini G, et al. Among authors: nasti g. Ann Oncol. 2005 Dec;16(12):1980-1. doi: 10.1093/annonc/mdi389. Epub 2005 Jul 20. Ann Oncol. 2005. PMID: 16033872 Free article. No abstract available.
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchini G, Daniele B, Di Blasi A, Napolitano M, Ieranò C, Calemma R, Leonardi E, Albino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R, Scala S. Ottaiano A, et al. Among authors: nasti g. Clin Cancer Res. 2006 May 1;12(9):2795-803. doi: 10.1158/1078-0432.CCR-05-2142. Clin Cancer Res. 2006. PMID: 16675573
213 results